Cure8 research brief
Cure8 research brief
MASLD was common in this IBD cohort and became more frequent as BMI increased; clinicians and patients may need to consider liver health when managing IBD, especially for people with overweight or obesity.
Adults with Crohn's disease or ulcerative colitis (particularly those with overweight or obesity), gastroenterology clinicians, hepatology clinicians, and researchers studying metabolic liver disease in IBD.
This is a retrospective chart review of 400 inpatients (2023–2024) that reconstructed MASLD status mainly from routine abdominal ultrasonography and supportive labs/indices. MASLD was present in ~45% overall and increased from ~20% in normal-BMI to ~66% in obesity. Severe IBD proportions rose across the same BMI strata.
Because the data come from routine care and the analysis was not adjusted for treatments, disease duration, or other metabolic covariates, the results show associations rather than proven cause-and-effect. The authors note MASLD was still present in about one-fifth of patients with normal BMI, so normal weight does not rule out steatotic liver disease.
If you have IBD, especially with overweight or obesity, talk to your clinician about whether liver screening (for example, ultrasound or liver enzymes) is appropriate; this study supports awareness but is not a guideline.
This is a medRxiv preprint (publish-ahead-of-print) reporting a retrospective single-cohort analysis using routine clinical data. It has not completed peer review. MASLD was reconstructed from routine imaging and records and study estimates were unadjusted for several potential confounders.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.